Aliases & Classifications for Excessive Tearing

MalaCards integrated aliases for Excessive Tearing:

Name: Excessive Tearing 12 15 73
Lacrimal Apparatus Diseases 44 73
Excessive Tear Production 12
Watering Eye 12
Epiphora 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13757
ICD10 33 H04.2 H04.20
ICD9CM 35 375.2 375.20
MeSH 44 D007766
NCIt 50 C50552
UMLS 73 C0152227

Summaries for Excessive Tearing

MalaCards based summary : Excessive Tearing, also known as lacrimal apparatus diseases, is related to early-onset glaucoma and lacrimal apparatus disease, and has symptoms including eye manifestations, dacryops and visual disturbance. An important gene associated with Excessive Tearing is DCXR (Dicarbonyl And L-Xylulose Reductase). The drugs Histamine and Fluticasone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin.

Related Diseases for Excessive Tearing

Diseases related to Excessive Tearing via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 early-onset glaucoma 30.8 CYP1B1 MYOC
2 lacrimal apparatus disease 12.3
3 epiphora due to insufficient drainage 11.9
4 epiphora due to excess lacrimation 11.9
5 bell's palsy 11.1
6 corneal dystrophy, epithelial basement membrane 10.8
7 tyrosinemia, type ii 10.8
8 cluster headache 10.8
9 acute inflammation of lacrimal passage 10.4 DCXR OPTN
10 dacryocystitis 10.4 DCXR OPTN
11 lacrimal duct obstruction 10.3 DCXR OPTN
12 megalocornea 10.2 LTBP2 OPTN
13 phacogenic glaucoma 10.2 LTBP2 OPTN
14 acrofrontofacionasal dysostosis 10.2 CYP1B1 OPTN
15 glaucoma 3, primary infantile, b 10.2 CYP1B1 LTBP2
16 chronic dacryocystitis 10.2 DCXR MLLT1
17 chronic inflammation of lacrimal passage 10.1 DCXR MLLT1
18 axenfeld-rieger syndrome 10.0 CYP1B1 OPTN
19 aniridia 1 9.9 CYP1B1 OPTN
20 hydrophthalmos 9.7 CYP1B1 LTBP2 OPTN
21 coloboma of macula 9.7 CYP1B1 OPTN
22 low tension glaucoma 9.7 MYOC OPTN
23 breast cancer 9.7
24 lacrimal duct defect 9.7
25 peritonitis 9.7
26 splenomegaly 9.7
27 ocular hypertension 9.6 MYOC OPTN
28 dry eye syndrome 9.6
29 optic nerve disease 9.5 MYOC OPTN
30 glaucoma 1, open angle, a 9.3 CYP1B1 MYOC OPTN
31 intraocular pressure quantitative trait locus 9.3 CYP1B1 MYOC OPTN
32 primary angle-closure glaucoma 9.3 CYP1B1 MYOC OPTN
33 juvenile glaucoma 9.3 CYP1B1 MYOC OPTN
34 glaucoma, primary open angle 9.2 CYP1B1 MYOC OPTN
35 nervous system disease 9.1 MYOC OPTN
36 corneal edema 8.8 CYP1B1 LTBP2 MYOC OPTN
37 primary congenital glaucoma 8.8 CYP1B1 LTBP2 MYOC OPTN
38 glaucoma 3, primary congenital, a 8.8 CYP1B1 LTBP2 MYOC OPTN
39 open-angle glaucoma 8.7 CYP1B1 LTBP2 MYOC OPTN

Graphical network of the top 20 diseases related to Excessive Tearing:



Diseases related to Excessive Tearing

Symptoms & Phenotypes for Excessive Tearing

UMLS symptoms related to Excessive Tearing:


eye manifestations, dacryops, visual disturbance, discharge from eye, watery eyes

Drugs & Therapeutics for Excessive Tearing

Drugs for Excessive Tearing (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
2
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 90566-53-3 62924
3
Fexofenadine Approved, Investigational Phase 4,Phase 3 83799-24-0 3348
4
Loratadine Approved, Investigational Phase 4,Phase 3 79794-75-5 3957
5
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
6
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
7
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Remifentanil Approved Phase 4 132875-61-7 60815
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
14
Cetirizine Approved Phase 4,Phase 2,Phase 3 83881-51-0 2678
15
Levocetirizine Approved Phase 4 130018-77-8 1549000
16
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
17
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
18
Alcaftadine Approved Phase 4 147084-10-4 19371515
19
Azelastine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58581-89-8 2267
20
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
21
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
22 Estradiol valerate Approved, Investigational, Vet_approved Phase 4 979-32-8
23
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
24
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
25
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
26
Polyestradiol phosphate Approved Phase 4 28014-46-2
27
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2 242138-07-4
28
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
29
Bromfenac Approved July 1997 Phase 4,Phase 3 91714-94-2 60726
30 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-74-1 65513
37 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Olopatadine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora Completed NCT01010659 Phase 4
2 Intranasal Steroids and the Nasal Ocular Response Completed NCT00473915 Phase 4 fluticasone furoate
3 Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse Completed NCT00196495 Phase 4
4 A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Completed NCT01469234 Phase 4 loratadine;fexofenadine;placebo to loratadine;placebo to fexofenadine
5 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
6 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms Completed NCT01007253 Phase 4 PL nasal spray;fluticasone furoate (FF);PL eye drops;olopatadine (OLO)
7 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
8 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
9 Recovery After Sugammadex(Propofol vs Sevoflurane) Completed NCT01579851 Phase 4 Sugammadex
10 A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis Completed NCT00653224 Phase 4 levocetirizine dihydrochloride;placebo
11 A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis Completed NCT00609674 Phase 4 Fluticasone furoate nasal spray;Placebo
12 Pain Management in Corneal Collagen Crosslinking for Keratoconus Completed NCT02867176 Phase 4 Gabapentin;Ketorolac
13 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
14 Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid Completed NCT00845195 Phase 4 Olopatadine HCl Nasal Spray, 0.6%;Azelastine HCl Nasal Spray, 0.1%
15 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial Completed NCT00691665 Phase 4 Olopatadine HCL Nasal Spray, 0.6%;Fluticasone Propionate Nasal Spray, 50 mcg
16 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
17 The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy Completed NCT01177514 Phase 4 Gabapentin;Sugar pill
18 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
19 A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Completed NCT01916226 Phase 4 FPNS;FPNS Placebo;Cetirizine;Cetirizine Placebo
20 A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber Completed NCT00848965 Phase 4 Fluticasone propionate;Placebo
21 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00502775 Phase 4 fluticasone furoate, fexofenadine
22 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
23 Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine Completed NCT00435461 Phase 4 Fluticasone furoate and fexofenadine
24 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
25 Bromfenac Versus Dexamethasone After Cataract Surgery Active, not recruiting NCT03317847 Phase 4 Bromfenac 0.09 % Ophthalmic Solution;Dexamethasone 0.1% ophthalmic suspension
26 The Effect of the Modified Perineal Protection Device During Delivery Unknown status NCT02013752 Phase 2, Phase 3
27 Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination Unknown status NCT01795599 Phase 3 Mifegyne ®;Gymiso®
28 Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Unknown status NCT02801617 Phase 3 PRO-067;GAAP Ofteno®
29 Assessment of Fluticasone Propionate on Ocular Allergy Symptoms Completed NCT01817790 Phase 3 Fluticasone propionate;Placebo
30 Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy Completed NCT01353079 Phase 3
31 Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old Completed NCT00780741 Phase 3
32 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) Completed NCT00783198 Phase 2, Phase 3
33 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Completed NCT00770315 Phase 2, Phase 3
34 Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis Completed NCT00884585 Phase 3 Cyclosporine Vehicle;Cyclosporine 0.010%
35 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. Completed NCT00769886 Phase 3 Ketotifen/naphazoline;Ketotifen;Naphazoline;Vehicle
36 Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. Completed NCT00770133 Phase 3 Ketotifen/naphazoline;Naphazoline;Ketotifen;Vehicle
37 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
38 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
39 Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis Completed NCT00423007 Phase 3 Bromfenac;Placebo
40 A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis Completed NCT01481519 Phase 3 dexamethasone 0.1%/povidone-iodine 0.4%;Artificial Tears
41 Trial of STAHIST in Seasonal Allergic Rhinitis Completed NCT01293201 Phase 3 STAHIST;Placebo
42 Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies Completed NCT00599872 Phase 3
43 Phase III Cat-PAD Follow-on Study Completed NCT02040844 Phase 3 Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762];Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
44 Trial of CF101 to Treat Patients With Dry Eye Disease Completed NCT01235234 Phase 3 CF101
45 Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis Completed NCT00244543 Phase 3 R89674 (generic name not yet established)
46 Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis Completed NCT00241319 Phase 3 R89674 (generic name not yet established)
47 Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822) Completed NCT00423995 Phase 3 Loratadine/montelukast combination
48 A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) Completed NCT01385371 Phase 3
49 Phase III Cat-PAD Study Completed NCT01620762 Phase 3 Cat-PAD;Placebo
50 Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis Completed NCT00409409 Phase 3 300 IR grass pollen allergen extract tablet;Placebo tablet

Search NIH Clinical Center for Excessive Tearing

Cochrane evidence based reviews: lacrimal apparatus diseases

Genetic Tests for Excessive Tearing

Anatomical Context for Excessive Tearing

MalaCards organs/tissues related to Excessive Tearing:

41
Eye, Testes, Skin, Thyroid, Brain, Liver, Breast

Publications for Excessive Tearing

Articles related to Excessive Tearing:

# Title Authors Year
1
Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. ( 23650421 )
2013
2
Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? ( 23650413 )
2013
3
Index of Suspicion. Case 1: Irritability and signs of peritonitis in a neonate. Case 2: Red eye, excessive tearing, photophobia, irritability, and splenomegaly in an infant. Case 3: 2-year-old girl who has cough, right pulmonary abnormalities. ( 22383516 )
2012
4
Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. ( 16645230 )
2006
5
Management of excessive tearing as a side effect of docetaxel. ( 15748466 )
2005
6
Excessive tearing in infancy and early childhood. The role and treatment of congenital nasolacrimal duct obstruction. ( 10865874 )
2000

Variations for Excessive Tearing

Expression for Excessive Tearing

Search GEO for disease gene expression data for Excessive Tearing.

Pathways for Excessive Tearing

GO Terms for Excessive Tearing

Cellular components related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.8 FGF10 LTBP2 MYOC

Biological processes related to Excessive Tearing according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood vessel morphogenesis GO:0048514 8.62 CYP1B1 FGF10

Sources for Excessive Tearing

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....